Clonal Hematopoiesis and Therapy-Emergent Myeloid Neoplasms in Patients With Cancers, CHANCES Study
Clonal Hematopoiesis and Therapy-Emergent Myeloid Neoplasms in Patients With Cancers (CHANCES)
Sponsor: National Cancer Institute (NCI)
This observational or N/A phase trial investigates Clonal Cytopenia of Undetermined Significance and Clonal Hematopoiesis and is currently actively recruiting participants. National Cancer Institute (NCI) leads this study, which shows 7 recorded versions since 2024 — indicating limited longitudinal coverage. As an oncology study, it adds to the longitudinal record of treatment development for this indication.
Study Description(click to expand)OUTLINE: This is an observational study.
Patients undergo blood sample collection and complete surveys on study. Patients' medical records are also reviewed.
OUTLINE: This is an observational study.
Patients undergo blood sample collection and complete surveys on study. Patients' medical records are also reviewed.
Status Flow
Change History
7 versions recorded-
Apr 18, 2026 — Present [daily]
Recruiting
-
Nov 2025 — Apr 2026 [monthly]
Recruiting
-
Apr 2025 — Nov 2025 [monthly]
Recruiting
-
Mar 2025 — Apr 2025 [monthly]
Recruiting
-
Sep 2024 — Mar 2025 [monthly]
Recruiting
▶ Show 2 earlier versions
-
Jul 2024 — Sep 2024 [monthly]
Recruiting
-
Apr 2024 — Jul 2024 [monthly]
Recruiting
First recorded
Jan 2024
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
This study is being done to investigate clonal hematopoiesis and therapy-emergent myeloid neoplasms in patients with ovarian or other solid cancers. Researchers want to identify risk factors for developing these blood cancers as well as if there is/are a genetic/environmental component(s) to developing blood cancer.
Contact Information
- National Cancer Institute (NCI)
- University of Washington
For direct contact, visit the study record on ClinicalTrials.gov .